Published in
Elsevier, Lancet Gastroenterology and Hepatology, 2023
DOI: 10.1016/s2468-1253(22)00428-9
Links
Tools
Efficacy and safety of gluten peptide-based antigen-specific immunotherapy (Nexvax2) in adults with coeliac disease after bolus exposure to gluten (RESET CeD): an interim analysis of a terminated randomised, double-blind, placebo-controlled phase 2 study
Journal article published in 2023 by
Jason A. Tye-Din 
,
A. James M. Daveson ,
Gautam Goel ,
Kaela E. Goldstein ,
Holly L. Hand ,
Kristin M. Neff ,
Alina Popp ,
Juha Taavela ,
Markku Maki ,
Jorma Isola ,
Leslie J. Williams ,
Kenneth E. Truitt ,
Robert P. Anderson ,
Atoya Adams,
Jane M. Andrews
and other authors.
,
A. James M. Daveson ,
Gautam Goel ,
Kaela E. Goldstein ,
Holly L. Hand ,
Kristin M. Neff ,
Alina Popp ,
Juha Taavela ,
Markku Maki ,
Jorma Isola ,
Leslie J. Williams ,
Kenneth E. Truitt ,
Robert P. Anderson ,
Atoya Adams,
Jane M. Andrews
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 